Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Targeted therapies in multiple myeloma Kastritis E; Charidimou A; Varkaris A; Dimopoulos MATarget Oncol 2009[Jan]; 4 (1): 23-36Increasing knowledge of the biology of multiple myeloma led the way for the development of novel drugs that have changed the management of the disease. New treatments target not only to the malignant plasma cell but also target the interactions of myeloma cells with their microenvironment. Several preclinical studies have identified potential targets and drugs are developed that act on pathways crucial for myeloma cell survival, proliferation, migration and drug resistance. The identification of active agents in the laboratory is followed by rationally designed clinical studies that validate these drugs, either as single agents or in combinations with other active drugs. These novel agents may be either small molecules or monoclonal antibodies targeting receptors, kinase activity of receptors or key molecules within critical pathways, intracellular maintenance mechanisms and immune modulation.|Animals[MESH]|Antibodies, Monoclonal/immunology/therapeutic use[MESH]|Antineoplastic Agents/*therapeutic use[MESH]|Cell Proliferation/drug effects[MESH]|Cell Survival/drug effects/immunology[MESH]|Clinical Trials as Topic[MESH]|Drug Design[MESH]|Enzyme Inhibitors/pharmacology/therapeutic use[MESH]|Humans[MESH]|Insulin-Like Growth Factor I/*antagonists & inhibitors/immunology[MESH]|Interleukin-6/*antagonists & inhibitors/immunology[MESH]|Multiple Myeloma/*drug therapy/immunology/metabolism/pathology[MESH]|NF-kappa B/antagonists & inhibitors[MESH]|Signal Transduction/drug effects/immunology[MESH]|Vascular Endothelial Growth Factor A/*antagonists & inhibitors[MESH] |
